Vaccine approach extends life of metastatic prostate cancer patients
Tuesday, January 26, 2010 - 07:35
in Health & Medicine
In a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumour cells lived substantially longer than patients who received a placebo vaccine, report researchers at Dana-Farber Cancer Institute and affiliated organisations. The findings will be published by the Journal of Clinical Oncology on its Web site and later in a print edition...